Oruka Therapeutics (ORKA) to Release Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, April 24th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.19. On average, analysts expect Oruka Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $10.58 on Wednesday. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13. The company has a fifty day moving average price of $10.09 and a two-hundred day moving average price of $17.10. The company has a market cap of $396.13 million, a PE ratio of -1.69 and a beta of 0.47.

Insider Buying and Selling

In other news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the purchase, the insider now directly owns 4,148,428 shares of the company’s stock, valued at approximately $47,458,016.32. The trade was a 2.19 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders acquired 98,339 shares of company stock valued at $1,128,456. Insiders own 22.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ORKA. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, Wolfe Research began coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price on the stock. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.